Solute carrier family 6 member 2. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Duloxetine CHEMBL1175 |
Norepinephrine transporter inhibitor Inhibitor Small molecule |
✓ Both | 17 |
| Methylphenidate CHEMBL796 |
Norepinephrine transporter inhibitor Inhibitor Small molecule |
✓ Both | 11 |
| Venlafaxine CHEMBL637 |
Norepinephrine transporter inhibitor Inhibitor Small molecule |
✓ Both | 8 |
| Bupropion CHEMBL894 |
Norepinephrine transporter inhibitor Inhibitor Small molecule |
✓ Both | 7 |
| Atomoxetine CHEMBL641 |
Norepinephrine transporter inhibitor Inhibitor Small molecule |
✓ Both | 3 |
| Lisdexamfetamine CHEMBL1201222 |
Norepinephrine transporter releasing agent Releasing agent Small molecule |
ChEMBL only | 3 |
| Reboxetine CHEMBL14370 |
Norepinephrine transporter inhibitor Inhibitor Small molecule |
ChEMBL only | 3 |
| Amitriptyline CHEMBL629 |
Norepinephrine transporter inhibitor Inhibitor Small molecule |
✓ Both | 2 |
| Desvenlafaxine CHEMBL1118 |
Norepinephrine transporter inhibitor Inhibitor Small molecule |
✓ Both | 2 |
| Esreboxetine CHEMBL180101 |
Norepinephrine transporter inhibitor Inhibitor Small molecule |
✓ Both | 2 |
| Midomafetamine HCl CHEMBL43048 |
Sodium-dependent noradrenaline transporter releasing agent Releasing agent Small molecule |
ChEMBL only | 2 |
| SPN-812 CHEMBL2106483 |
Norepinephrine transporter inhibitor Inhibitor Small molecule |
ChEMBL only | 2 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Fibromyalgia | 5 | Phase 3 |
| Autism spectrum disorder | 4 | Phase 3 |
| Bipolar disorder | 4 | Phase 3 |
| Pain | 3 | Phase 3 |
| Depressive disorder | 3 | Phase 3 |
| Neuropathic pain | 3 | Phase 3 |
| Post-traumatic stress disorder | 3 | Phase 3 |
| Schizophrenia | 3 | Phase 3 |
| Social phobia | 3 | Phase 3 |
| Alzheimer disease | 2 | Phase 3 |
| Apathy | 2 | Phase 3 |
| Cognitive impairment | 2 | Phase 3 |
| Knee pain | 2 | Phase 3 |
| Parkinson disease | 2 | Phase 3 |
| Anxiety | 2 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
